Unión Europea - español - EMA (European Medicines Agency)

recordati netherlands b.v. - tivozanib - carcinoma, células renales - agentes antineoplásicos - fotivda está indicado para el tratamiento de primera línea de pacientes adultos con carcinoma avanzado de células renales (rcc) y para pacientes adultos que vegfr y mtor vía inhibidor no siguen la progresión de la enfermedad después de un tratamiento previo con terapia del cytokine para rcc avanzado. tratamiento de carcinoma de células renales avanzado.

Unión Europea - español - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agentes antineoplásicos - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq como monoterapia está indicado para el tratamiento de pacientes adultos con localmente avanzado o metastásico de pulmón no microcítico después de la quimioterapia previa. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

novartis pharma stein ag, stein, suiza. novartis pharma ag, basel, suiza. - (everolimus) - tableta - 5,0 mg

Cuba - español - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

bayer pharma ag, leverkusen, alemania. - regorafenib - comprimido recubierto - 40,0 mg

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoma, pulmón no microcítico - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

biotoscana farma de peru s.a.c. - droguerÍa - capsula dura - por capsula - - lenvatinib

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

avalon pharmaceutical peru s.a.c. - droguerÍa - concentrado de enzimas proteolíticas enriquecidas en bromelaína - polvo y gel para gel - 5g - por dosis g - - enzimas

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

biotoscana farma de peru s.a.c. - droguerÍa - capsula dura - por capsula - - lenvatinib

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

biotoscana farma de peru s.a.c. - droguerÍa - capsula dura - por capsula - - lenvatinib

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

biotoscana farma de peru s.a.c. - droguerÍa - capsula dura - por capsula - - lenvatinib